Final answer:
The first line treatment for Kawasaki disease consists of intravenous immunoglobulin and aspirin, aimed at reducing inflammation and preventing coronary artery complications.
Step-by-step explanation:
The first line treatment for Kawasaki disease (KD), also known as mucocutaneous lymph node syndrome, primarily involves the administration of intravenous immunoglobulin (IVIG) and aspirin. IVIG is typically given in a single high dose, which has been shown to significantly reduce the risk of coronary artery abnormalities, a major complication of the disease. Aspirin is used at anti-inflammatory doses initially and then at lower antiplatelet doses once the child is afebrile. The treatment aims to reduce inflammation and prevent the development of coronary artery issues. Timely treatment of Kawasaki disease is critical to prevent long-term cardiac complications.